Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01146002 · ClinicalTrials.gov registry record · Phase 4
Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine
A Phase 4 study of Attention Deficit/Hyperactivity Disorder, sponsored by Neurology Group of Bergen County, P.A..
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT01146002 is a Phase 4 study of Attention Deficit/Hyperactivity Disorder that has completed, run by Neurology Group of Bergen County, P.A.. The registered enrollment target is 30 participants, below the 297-participant average among 13 other Attention Deficit/Hyperactivity Disorder trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01146002, a Phase 4 study of Attention Deficit/Hyperactivity Disorder, has completed, sponsored by Neurology Group of Bergen County, P.A..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is investigating the effect of sustained-release guanfacine (Intuniv) on language-based learning skills in children age 6-12 who are diagnosed with attention deficit hyperactivity disorder (ADHD).
Conditions Studied
Interventions
- DRUG Guanfacine (sustained release)
Study Locations (1)
New Jersey
- Neurology Group of Bergen County - Ridgewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-06 |
| Est. Completion | 2013-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01146002
The ClinicalTrials.gov registry entry for NCT01146002 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 297-participant average among 13 other Attention Deficit/Hyperactivity Disorder trials with a reported enrollment target (90% lower). The listed sponsor is Neurology Group of Bergen County, P.A., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Attention Deficit/Hyperactivity Disorder appearing as the primary indexed condition, and to 1 intervention - of which Guanfacine (sustained release) is the first listed.
NCT01146002 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT01146002 about?
NCT01146002 is a clinical study titled "Language-based Learning Skills and Attention Deficit Hyperactivity Disorder (ADHD): Impact of Treatment With Sustained-release Guanfacine". This study is investigating the effect of sustained-release guanfacine (Intuniv) on language-based learning skills in children age 6-12 who are diagnosed with attention deficit hyperactivity disorder (ADHD).
What is the current status of trial NCT01146002?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2010-06. Estimated completion is 2013-02.
What conditions does trial NCT01146002 study?
This clinical trial studies the following conditions: Attention Deficit/Hyperactivity Disorder.
What interventions are being tested in trial NCT01146002?
The interventions under investigation include: Guanfacine (sustained release) (DRUG).
Who is sponsoring clinical trial NCT01146002?
This trial is sponsored by Neurology Group of Bergen County, P.A., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01146002 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Attention Deficit/Hyperactivity Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
RECRUITING · Phase 4
-
An Open-Label Treatment With Randomization Observation, Investigator-Initiated Study, on the Duration and Efficacy of Jornay PM (Methylphenidate Hydrochloride Extended-Release Capsules) on Adult ADHD Symptoms and Executive Function and Emotional Regulation Throughout the Day Into Early Evening
RECRUITING · Phase 4
-
Focus Groups in Ethnically and Racially Diverse Families
RECRUITING
-
Optimizing Research With Diverse Families - Feasibility and Acceptability Study (FAST)
RECRUITING · NA
-
The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
RECRUITING · Phase 2
-
A Pilot Study of a Remote ADHD Monitoring Program
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.